- Home
- SGN vs BDRX Comparison
SGN vs BDRX Comparison
Compare SGN & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- BDRX
- Stock Information
- Founded
- SGN 2019
- BDRX 2000
- Country
- SGN United States
- BDRX United Kingdom
- Employees
- SGN N/A
- BDRX N/A
- Industry
- SGN
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- SGN
- BDRX Health Care
- Exchange
- SGN Nasdaq
- BDRX Nasdaq
- Market Cap
- SGN 3.8M
- BDRX 3.8M
- IPO Year
- SGN 2023
- BDRX N/A
- Fundamental
- Price
- SGN $1.59
- BDRX $5.65
- Analyst Decision
- SGN
- BDRX
- Analyst Count
- SGN 0
- BDRX 0
- Target Price
- SGN N/A
- BDRX N/A
- AVG Volume (30 Days)
- SGN 284.6K
- BDRX 22.8K
- Earning Date
- SGN 08-12-2025
- BDRX 09-29-2025
- Dividend Yield
- SGN N/A
- BDRX N/A
- EPS Growth
- SGN N/A
- BDRX N/A
- EPS
- SGN N/A
- BDRX N/A
- Revenue
- SGN $391,126.00
- BDRX N/A
- Revenue This Year
- SGN N/A
- BDRX N/A
- Revenue Next Year
- SGN N/A
- BDRX N/A
- P/E Ratio
- SGN N/A
- BDRX N/A
- Revenue Growth
- SGN N/A
- BDRX N/A
- 52 Week Low
- SGN $0.44
- BDRX $5.29
- 52 Week High
- SGN $36.70
- BDRX $112.85
- Technical
- Relative Strength Index (RSI)
- SGN 52.64
- BDRX 34.03
- Support Level
- SGN $1.47
- BDRX $5.29
- Resistance Level
- SGN $1.65
- BDRX $5.96
- Average True Range (ATR)
- SGN 0.10
- BDRX 0.48
- MACD
- SGN 0.00
- BDRX 0.01
- Stochastic Oscillator
- SGN 71.13
- BDRX 18.55
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.